|
1
|
No authors listed, . Brain tumor registry
of Japan (2005–2008). Neurol Med Chir (Tokyo). 57 (Suppl
1):S9–S102. 2017. View Article : Google Scholar
|
|
2
|
Knudsen-Baas KM, Engeland A, Gilhus NE,
Storstein AM and Owe JF: Does the choice of antiepileptic drug
affect survival in glioblastoma patients? J Neurooncol.
129:461–469. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Weller M, Gorlia T, Cairncross JG, van den
Bent MJ, Mason W, Belanger K, Brandes AA, Bogdahn U, Macdonald DR,
Forsyth P, et al: Prolonged survival with valproic acid use in the
EORTC/NCIC temozolomide trial for glioblastoma. Neurology.
77:1156–1164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barker CA, Bishop AJ, Chang M, Beal K and
Chan TA: Valproic acid use during radiation therapy for
glioblastoma associated with improved survival. Int J Radiat Oncol
Biol Phys. 86:504–509. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jabbarli R, Ahmadipour Y, Rauschenbach L,
Santos AN, Darkwah Oppong M, Pierscianek D, Quesada CM, Kebir S,
Dammann P, Guberina N, et al: How about levetiracetam in
glioblastoma? An institutional experience and meta-analysis.
Cancers (Basel). 13:37702021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Happold C, Gorlia T, Chinot O, Gilbert MR,
Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, et al:
Does valproic acid or levetiracetam improve survival in
glioblastoma? A pooled analysis of prospective clinical trials in
newly diagnosed glioblastoma. J Clin Oncol. 34:731–739. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
French JA, Krauss GL, Biton V, Squillacote
D, Yang H, Laurenza A, Kumar D and Rogawski MA: Adjunctive
perampanel for refractory partial-onset seizures: Randomized phase
III study 304. Neurology. 79:589–596. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Grossman SA, Ye X, Chamberlain M,
Mikkelsen T, Batchelor T, Desideri S, Piantadosi S, Fisher J and
Fine HA: Talampanel with standard radiation and temozolomide in
patients with newly diagnosed glioblastoma: A multicenter phase II
trial. J Clin Oncol. 27:4155–4161. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Iwamoto FM, Kreisl TN, Kim L, Duic JP,
Butman JA, Albert PS and Fine HA: Phase 2 trial of talampanel, a
glutamate receptor inhibitor, for adults with recurrent malignant
gliomas. Cancer. 116:1776–1782. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lange F, Weßlau K, Porath K, Hörnschemeyer
J, Bergner C, Krause BJ, Mullins CS, Linnebacher M, Köhling R and
Kirschstein T: AMPA receptor antagonist perampanel affects
glioblastoma cell growth and glutamate release in vitro. PLoS One.
14:e02116442019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salmaggi A, Corno C, Maschio M, Donzelli
S, D'Urso A, Perego P and Ciusani E: Synergistic effect of
perampanel and temozolomide in human glioma cell lines. J Pers Med.
11:3902021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Izumoto S, Miyauchi M, Tasaki T, Okuda T,
Nakagawa N, Nakano N, Kato A and Fujita M: Seizures and tumor
progression in glioma patients with uncontrollable epilepsy treated
with perampanel. Anticancer Res. 38:4361–4366. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tatsuoka J, Sano E, Hanashima Y, Yagi C,
Yamamuro S, Sumi K, Hara H, Takada K, Kanemaru K, Komine-Aizawa S,
et al: Anti-tumor effects of perampanel in malignant glioma cells.
Oncol Lett. 24:4212022. View Article : Google Scholar
|
|
14
|
Lefranc F, Le Rhun E, Kiss R and Weller M:
Glioblastoma quo vadis: Will migration and invasiveness reemerge as
therapeutic targets? Cancer Treat Rev. 68:145–154. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Corsi L, Mescola A and Alessandrini A:
Glutamate receptors and glioblastoma multiforme: An old ‘route’ for
new perspectives. Int J Mol Sci. 20:17962019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vollmann-Zwerenz A, Leidgens V, Feliciello
G, Klein CA and Hau P: Tumor cell invasion in glioblastoma. Int J
Mol Sci. 21:19322020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Piao Y, Lu L and de Groot J: AMPA
receptors promote perivascular glioma invasion via beta1
integrin-dependent adhesion to the extracellular matrix. Neuro
Oncol. 11:260–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhong J, Paul A, Kellie SJ and O'Neill GM:
Mesenchymal migration as a therapeutic target in glioblastoma. J
Oncol. 2010:4301422010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Catalano M, D'Alessandro G, Lepore F,
Corazzari M, Caldarola S, Valacca C, Faienza F, Esposito V,
Limatola C, Cecconi F and Di Bartolomeo S: Autophagy induction
impairs migration and invasion by reversing EMT in glioblastoma
cells. Mol Oncol. 9:1612–1625. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu X, Hu B, Hu M, Qian D and Wang B:
Human cytomegalovirus infection enhances invasiveness and migration
of glioblastoma cells by epithelial-to-mesenchymal transition. Int
J Clin Exp Pathol. 13:2637–2647. 2020.PubMed/NCBI
|
|
21
|
Cuddapah VA, Robel S, Watkins S and
Sontheimer H: A neurocentric perspective on glioma invasion. Nat
Rev Neurosci. 15:455–465. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yoshino A, Ogino A, Yachi K, Ohta T,
Fukushima T, Watanabe T, Katayama Y, Okamoto Y, Naruse N, Sano E
and Tsumoto K: Gene expression profiling predicts response to
temozolomide in malignant gliomas. Int J Oncol. 36:1367–1377. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wischhusen J, Naumann U, Ohgaki H,
Rastinejad F and Weller M: CP-31398, a novel p53-stabilizing agent,
induces p53-dependent and p53-independent glioma cell death.
Oncogene. 22:8233–8245. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Japanese Society of Neurology, . CQ12-2:
Serum concentration monitoring is useful for which drugs? Clinical
practice guidelines for epilepsy 2018. Igaku-Shoin Ltd; Tokyo: pp.
103–105. 2018, Available at:. https://neurology-jp.org/guidelinem/epilepsy/documents/guideline2018.pdfpp.
123–125. https://www.neurology-jp.org/guidelinem/tenkan_2018.htmlin
Japanese.
|
|
25
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brodie MJ, Covanis A, Gil-Nagel A, Lerche
H, Perucca E, Sills GJ and White HS: Antiepileptic drug therapy:
Does mechanism of action matter? Epilepsy Behav. 21:331–341. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang C, Liu S, Yuan X, Hu Z, Li H, Wu M,
Yuan J, Zhao Z, Su J, Wang X, et al: Valproic acid promotes human
glioma U87 cells apoptosis and inhibits glycogen synthase kinase-3β
through ERK/Akt signaling. Cell Physiol Biochem. 39:2173–2185.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Han W and Guan W: Valproic acid: A
promising therapeutic agent in glioma treatment. Front Oncol.
11:6873622021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bello MJ, Alonso ME, Amiñoso C, Anselmo
NP, Arjona D, Gonzalez-Gomez P, Lopez-Marin I, de Campos JM,
Gutierrez M, Isla A, et al: Hypermethylation of the DNA repair gene
MGMT: Association with TP53 G:C to A:T transitions in a series of
469 nervous system tumors. Mutat Res. 554:23–32. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Scicchitano BM, Sorrentino S, Proietti G,
Lama G, Dobrowolny G, Catizone A, Binda E, Larocca LM and Sica G:
Levetiracetam enhances the temozolomide effect on glioblastoma stem
cell proliferation and apoptosis. Cancer Cell Int. 18:1362018.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
de Bruin ME, van der Meer PB, Dirven L,
Taphoorn MJB and Koekkoek JAF: Efficacy of antiepileptic drugs in
glioma patients with epilepsy: A systematic review. Neurooncol
Pract. 8:501–517. 2021.PubMed/NCBI
|
|
33
|
Galvao J, Davis B, Tilley M, Normando E,
Duchen MR and Cordeiro MF: Unexpected low-dose toxicity of the
universal solvent DMSO. FASEB J. 28:1317–1330. 2014. View Article : Google Scholar : PubMed/NCBI
|
